About: Uterine serous carcinoma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Uterine serous carcinoma Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

medical condition

Attributes	Values
rdf:type	Item
description	medical condition (en) медичний стан (uk)
Experimental Factor Ontology ID	wds:Q7902657-873FFB80-F3DC-4E06-8371-AA7C5FA8C075
ICD-10	wds:q7902657-70746725-83A9-4B9E-95B7-984613A9849B
Mondo ID	wds:Q7902657-4EC93618-2B70-4E3F-B8CA-719FBBFB1DB1
Mondo ID	http://purl.obolibrary.org/obo/MONDO_0006196
Experimental Factor Ontology ID	1000238
ICD-10	C54.1
Mondo ID	MONDO_0006196
rdfs:label	ഗർഭാശയത്തിലെ സീറസ് കാർസിനോമ (ml) Uterine serous carcinoma (en) carcinomes papillaires séreux ovarien (fr) serozni karcinom maternice (sl) سرطانة مصلية حليمية رحمية (ar) 子宫乳头状浆液性癌 (zh)
skos:prefLabel	ഗർഭാശയത്തിലെ സീറസ് കാർസിനോമ (ml) Uterine serous carcinoma (en) carcinomes papillaires séreux ovarien (fr) serozni karcinom maternice (sl) سرطانة مصلية حليمية رحمية (ar) 子宫乳头状浆液性癌 (zh)
name	ഗർഭാശയത്തിലെ സീറസ് കാർസിനോമ (ml) Uterine serous carcinoma (en) carcinomes papillaires séreux ovarien (fr) serozni karcinom maternice (sl) سرطانة مصلية حليمية رحمية (ar) 子宫乳头状浆液性癌 (zh)
subclass of	wds:Q7902657-57410140-D96A-4860-86D0-4BF8B6FE331C wds:Q7902657-5c76a246-4602-223c-e92c-899231d9618e wds:Q7902657-76efbaab-4698-8cf5-9d3e-fa02f41df812
subclass of	uterine cancer endometrial carcinoma serous cystadenocarcinoma
PatientsLikeMe condition ID	wds:Q7902657-fdf9a712-4007-abff-2797-70dfd8ab0a1e
PatientsLikeMe condition ID	uterine-serous-carcinoma
Medical Dictionary...ory Activities ID	wds:Q7902657-BA50EB7C-CAB5-40B9-B734-6DE9A2F6BEDA
ICD-9 ID	wds:q7902657-E6846BDE-F48B-445F-89F0-ADDC553FE778
Medical Dictionary...ory Activities ID	http://purl.bioontology.org/ontology/MDRFRE/10014760
Medical Dictionary...ory Activities ID	10014760
ICD-9 ID	182
skos:altLabel	uterine papillary serous carcinoma (en) Endometrial Serous Adenocarcinoma (en) Serous endometrial adenocarcinoma (en) Uterine Corpus Serous Adenocarcinoma (en) Uterine Serous Carcinoma (en) Uterine Serous Papillary Adenocarcinoma (en) Uterine serous carcinoma, USC (en) adénocarcinome séreux de l'ovaire (fr) carcinome séreux de l'ovaire (fr) uterine serous adenocarcinoma (en)
NCI Thesaurus ID	wds:Q7902657-AED13114-0144-402D-9B45-1F7E3BE7DAFA
UMLS CUI	wds:Q7902657-a950000b-43ce-53ce-8e3e-691aefb0972f
Microsoft Academic ID	wds:Q7902657-857FB895-B13F-4C95-8A02-4FC0514E65B3
Microsoft Academic ID	https://makg.org/entity/2776802242
NCI Thesaurus ID	C27838
UMLS CUI	C0854924
Microsoft Academic ID	2776802242
is field of work of	Amanda Fader
is field of work of	wds:Q114338146-f7bd2b82-4d72-0bbb-d55a-2621f5137549
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q7902657 Uterine serous carcinoma https://zh.wikipedia.org/wiki/%E5%AD%90%E5%AE%AB%E4%B9%B3%E5%A4%B4%E7%8A%B6%E6%B5%86%E6%B6%B2%E6%80%A7%E7%99%8C https://ar.wikipedia.org/wiki/%D8%B3%D8%B1%D8%B7%D8%A7%D9%86%D8%A9_%D9%85%D8%B5%D9%84%D9%8A%D8%A9_%D8%AD%D9%84%D9%8A%D9%85%D9%8A%D8%A9_%D8%B1%D8%AD%D9%85%D9%8A%D8%A9 https://ml.wikipedia.org/wiki/%E0%B4%97%E0%B5%BC%E0%B4%AD%E0%B4%BE%E0%B4%B6%E0%B4%AF%E0%B4%A4%E0%B5%8D%E0%B4%A4%E0%B4%BF%E0%B4%B2%E0%B5%86_%E0%B4%B8%E0%B5%80%E0%B4%B1%E0%B4%B8%E0%B5%8D_%E0%B4%95%E0%B4%BE%E0%B5%BC%E0%B4%B8%E0%B4%BF%E0%B4%A8%E0%B5%8B%E0%B4%AE
is main subject of	Somatic D-loop mitochondrial DNA mutations are frequent in uterine serous carcinoma WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. Comparison of outcomes in early stage uterine carcinosarcoma and uterine serous carcinoma Minimal uterine serous carcinoma: a clinicopathological study of 40 cases Early stage uterine serous carcinoma: management updates and genomic advances Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2). Clinical significance of Her-2/neu overexpression in uterine serous carcinoma Correlation of tumor size with other prognostic factors in uterine serous carcinoma: a large multi-institutional study Outcomes of patients with uterine serous carcinoma using the revised FIGO staging system Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation Uterine serous carcinoma and endometrial intraepithelial carcinoma arising in endometrial polyps: report of 5 cases, including 2 associated with tamoxifen therapy Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners p53 Regulates insulin-like growth factor-I receptor gene expression in uterine serous carcinoma and predicts responsiveness to an insulin-like growth factor-I receptor-directed targeted therapy Comparison of Survival Benefits of Combined Chemotherapy and Radiotherapy Versus Chemotherapy Alone for Uterine Serous Carcinoma: A Meta-analysis Patterns of care, associations and outcomes of chemotherapy for uterine serous carcinoma: analysis of the National Cancer Database p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma Population-based treatment and outcomes of Stage I uterine serous carcinoma Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study Association between uterine serous carcinoma and breast cancer CA 125 may not reflect disease status in patients with uterine serous carcinoma Complete clinical responses to neoadjuvant chemotherapy for uterine serous carcinoma Uterine serous carcinoma: a comparison of therapy for advanced-stage disease IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software